A federal judge Thursday froze profits held in U.S. brokerage accounts that government officials believe were generated by insider information related to GlaxoSmithKline’s Oct. 9 $566 million purchase of CNS Inc., the maker of Breathe-Right nasal strips.

The Securities and Exchange Commission requested the freeze last week after discovering five separate call option contracts on the common stock of CNS placed by unidentified individuals.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]